D. Vallera

J. Wagner, Jeffrey S. Miller, D. Vallera, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome.

D. Snover, B. Blazar, P. Taylor, 1993, Journal of immunology.

BONE MARROW TRANSPLANTATION ACROSS MAJOR HISTOCOMPATIBILITY BARRIERS IN MICE EFFECT OF ELIMINATION OF T CELLS FROM DONOR GRAFTS BY TREATMENT WITH MONOCLONAL THY‐1.2 PLUS COMPLEMENT OR ANTIBODY ALONE

J. Kersey, D. Vallera, G. J. Carlson, 1981, Transplantation.

A trispecific killer engager molecule against CLEC12A effectively induces NK cell mediated killing of AML cells

Jeffrey S. Miller, B. Blazar, D. Vallera, 2020, Leukemia.

An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells

D. Vallera, Nate N. Waldron, 2013 .

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma

S. Barsky, D. Vallera, P. Dougherty, 2013, Targeted Oncology.

In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts.

B. Bostrom, B. Blazar, J. Kersey, 1989, Blood.

Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts.

S. Smith, B. Blazar, P. Taylor, 1995, Blood.

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.

Jeffrey S. Miller, J. Gotlib, D. Vallera, 2018, Blood advances.

The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.

G. Gray, B. Blazar, P. Taylor, 1997, Blood.

Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging.

J. Ledbetter, F. Uckun, D. Weisdorf, 1990, Blood.

Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation.

Jeffrey S. Miller, B. Blazar, J. Riley, 2021, Blood advances.

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition

Bin Zhang, Jeffrey S. Miller, J. Ross, 2013, Clinical Cancer Research.

Murine ylS-Expressing T Cells Affect Alloengraftment Via the Recognition of Nonclassical Major Histocompatibility Complex Class Ib Antigens

J. Bluestone, P. Taylor, D. Vallera, 2002 .

IN UTERO ENGRAFTMENT OF FULLY H‐2-INCOMPATIBLE VERSUS CONGENIC ADULT BONE MARROW TRANSFERRED INTO NONANEMIC OR ANEMIC MURINE FETAL RECIPIENTS

B. Blazar, D. Vallera, Y. Matloub, 1993, Transplantation.

Bispeci ﬁ c and Trispeci ﬁ c Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

L. Weiner, D. Vallera, D. Todhunter, 2012 .

Identification and characterization of a novel scFv recognizing human and mouse CD133

J. Panyam, D. Vallera, J. Ohlfest, 2013, Drug Delivery and Translational Research.

antigens Ib recognition of nonclassical major histocompatibility complex class Murine gamma/delta-expressing T cells affect alloengraftment via the

B. Blazar, P. Taylor, D. Vallera, 2011 .

ABSENCE OF A FACILITORY ROLE FOR NK 1.1‐POSITIVE DONOR CELLS IN ENGRAFTMENT ACROSS A MAJOR HISTOCOMPATIBILITY BARRIER IN MICE1,2

B. Blazar, D. Vallera, G. Koo, 1988, Transplantation.

Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease.

M. Roncarolo, S. Narula, B. Blazar, 1998, Transplantation.

Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice

W. Hall, W. Low, Haiying Liu, 2006, International journal of cancer.

Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker

Jeffrey S. Miller, D. Vallera, D. Todhunter, 2016, Oncotarget.

Immunotoxins: will their clinical promise be fulfilled?

D. Vallera, 1994, Blood.

Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins.

R. Youle, D. Vallera, R. Stong, 1984, Cancer research.

Release of soluble "blocking" and "suppressor" factors from normal lymphocytes treated with RNA from spleens of tumour-bearing mice.

J. Nawrocki, D. Vallera, M. Dodd, 1979, British Journal of Cancer.

Anti-tumour cytotoxicity of poly(A)-containing messenger RNA isolated from tumour-specific immunogenic RNA.

D. Vallera, M. Dodd, K. Pennline, 1978, British Journal of Cancer.

Immunotoxins: will their clinical promise be fulfilled?

D. Vallera, 1994, Blood.

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.

Jeffrey S. Miller, D. Weisdorf, V. Bachanova, 2019, Blood advances.

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL

M. Uhrberg, S. Bhatia, D. Vallera, 2021, Cancer Immunology, Immunotherapy.

progeny with T- and B-cell functional capabilities severe combined immunodeficiency disorder yields lymphoid In utero transfer of adult bone marrow cells into recipients with

B. Blazar, P. Taylor, D. Vallera, 2011 .

NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo

S. Ferrone, Jeffrey S. Miller, C. Ryan, 2020, Cancers.

Immunotoxins for ex vivo bone marrow purging in human bone marrow transplantation.

D. Vallera, 1988, Cancer treatment and research.

Interleukin-1 alpha-mediated promotion of long-term alloengraftment and short-term neutrophil expansion does not require the presence of either donor or host T cells.

B. Blazar, P. Taylor, D. Vallera, 1996, Transplantation.

Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity

A. LeBeau, Jeffrey S. Miller, J. Panyam, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells

J. Miller, D. Vallera, M. Gleason, 2016, Targeted Oncology.

A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells.

C. Eide, B. Blazar, D. Vallera, 1995, Blood.

Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia

F. Uckun, J. Kersey, D. Vallera, 1986, The Journal of experimental medicine.

Bone marrow transplantation across major histocompatibility barriers in mice. IV. Graft-versus-host disease in TLI-conditioned mice.

J. Kersey, D. Vallera, A. Filipovich, 1982, Clinical Immunology and Immunopathology.

Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.

D. Kaufman, L. Weiner, Bin Zhang, 2013, Cancer biotherapy & radiopharmaceuticals.

The relative immunogenicity of murine tissues in vivo.

D. Vallera, S. Mentzer, R. Ferguson, 1980, Current surgery.

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors

J. Modiano, V. Bachanova, D. Vallera, 2020, Biomolecules.

A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer

M. Geller, D. Vallera, M. Felices, 2021, Cancers.

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

L. Weiner, Bin Zhang, Jeffrey S. Miller, 2012, Molecular Cancer Therapeutics.

Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.

Jeffrey S. Miller, D. Vallera, Z. Davis, 2017, Seminars in immunology.

Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.

Jeffrey S. Miller, D. Vallera, Z. Davis, 2016, Methods in molecular biology.

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity

B. Stish, R. Kratzke, D. Vallera, 2009, British Journal of Cancer.

Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation.

R. Youle, F. Uckun, J. Kersey, 1985, Blood.

Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.

A. Frankel, J. Kersey, D. Vallera, 1996, Journal of immunological methods.

Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.

B. Jansen, J. Kersey, D. Vallera, 1992, Cancer research.

Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin

D. Vallera, M. Schabet, U. Herrlinger, 1998, Journal of Neuro-Oncology.

Targeting T cells for GVHD therapy.

D. Vallera, 1996, Seminars in Cancer Biology.

Targeting the Over-Expressed Urokinase-Type Plasminogen Activator Receptor on Glioblastoma Multiforme

W. Hall, D. Vallera, E. Rustamzadeh, 2003, Journal of Neuro-Oncology.

Enhanced survival but reduced engraftment in murine recipients of recombinant granulocyte/macrophage colony-stimulating factor following transplantation of T-cell-depleted histoincompatible bone marrow.

B. Blazar, D. Vallera, S. Gillis, 1988, Blood.

Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development

D. Vallera, D. Todhunter, J. Schmohl, 2015, Toxins.

Molecular modification of a recombinant anti-CD3epsilon-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model.

B. Blazar, D. Vallera, D. Buchsbaum, 2000, Blood.

Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor.

C. Eide, B. Blazar, D. Vallera, 1996, Blood.

Diphtheria toxin-based targeted toxins that target glioblastoma multiforme

W. Hall, D. Vallera, Y. M. Li, 2014 .

Diphtheria toxin-based targeted toxin therapy for brain tumors

W. Hall, D. Vallera, Y. M. Li, 2013, Journal of Neuro-Oncology.

Targeting myeloid leukemia with a DT(390)-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice.

J. Griffin, B. Blazar, D. Vallera, 1999, Protein engineering.

Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.

G. Stefanzl, T. Rülicke, P. Valent, 2020, Blood advances.

Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.

W. Hall, D. Vallera, D. Todhunter, 2002, Protein engineering.

Reactivity of murine cytokine fusion toxin, diphtheria toxin390-murine interleukin-3 (DT390-mIL-3), with bone marrow progenitor cells.

B. Blazar, D. Vallera, L. Greenfield, 1996, Blood.

Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia.

A I Goldman, B Bostrom, W. Woods, 1987, The New England journal of medicine.

Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR

K. Lindblad-Toh, J. Koopmeiners, Jonathan C. Henriksen, 2017, Molecular Cancer Therapeutics.

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer

I. Pastan, R. Kratzke, D. Vallera, 2023, Frontiers in Immunology.

Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.

A. Sharpe, G. Gray, R. Korngold, 1996, Journal of immunology.

Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts.

G. Gray, B. Blazar, P. Taylor, 1995, Blood.

Transgenic mice expressing either bovine growth hormone (bGH) or human GH releasing hormone (hGRH) have increased splenic progenitor cell colony formation and DNA synthesis in vitro and in vivo.

H. Broxmeyer, L. Shultz, B. Blazar, 1995, Experimental hematology.

Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.

A. Sharpe, B. Blazar, P. Taylor, 1999, Journal of immunology.

of recombinant human interleukin-1 alpha (see comments) administration recovery across the major histocompatibility barrier by Promotion of murine marrow alloengraftment and hematopoietic

B. Blazar, D. Vallera, M. Widmer, 2011 .

Promotion of murine marrow alloengraftment and hematopoietic recovery across the major histocompatibility barrier by administration of recombinant human interleukin-1 alpha.

B. Blazar, P. Taylor, D. Vallera, 1992, Blood.

A critical role for CD48 antigen in regulating alloengraftment and lymphohematopoietic recovery after bone marrow transplantation.

J. Bromberg, B. Blazar, H. Yagita, 1998, Blood.

A Critical Role for CD 48 Antigen in Regulating Alloengraftment and Lymphohematopoietic Recovery After Bone Marrow Transplantation

J. Bromberg, B. Blazar, H. Yagita, 1998 .

A Deimmunized Bispecific Ligand-Directed Toxin That Shows an Impressive Anti–Pancreatic Cancer Effect in a Systemic Nude Mouse Orthotopic Model

D. Vallera, D. Buchsbaum, D. Todhunter, 2012, Pancreas.

Monoclonal antibodies and immunotoxins in bone marrow transplantation: purging marrow of ALL or GVHD cells with preservation of stem cells.

D. Neville, R. Youle, T. Lebien, 1985, Haematology and blood transfusion.

Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.

B. Blazar, P. Taylor, D. Vallera, 1998, Journal of immunology.

Cytotoxic Cytokines Interfering with the Production of Th 1 or Th 1 Graft-Versus-Leukemia-Causing T Cells by Graft-Versus-Host Disease-and Rapamycin Inhibits the Generation of and

B. Blazar, P. Taylor, D. Vallera, 1998 .

Design, Characterization, and Evaluation of scFvCD133/rGelonin: A CD133-Targeting Recombinant Immunotoxin for Use in Combination with Photochemical Internalization

K. Berg, M. Rosenblum, A. Weyergang, 2019, Journal of clinical medicine.

A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.

C. Song, B. Blazar, D. Vallera, 1985, Journal of immunology.

470 Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors

Jeffrey S. Miller, D. Vallera, Bahram Valamehr, 2020 .

Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor--immunotoxin target gene.

B. Blazar, D. Vallera, S. Ramakrishnan, 2002, Human gene therapy.

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

D. Munn, J. Tolar, B. Levine, 2010, Blood.

murine recipients by granulocyte/macrophage colony-stimulating factor Augmentation of donor bone marrow engraftment in histoincompatible

B. Blazar, D. Vallera, S. Gillis, 2011 .

in Mice Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation Keratinocyte Growth Factor Administered Before Conditioning Ameliorates

D. Lacey, B. Blazar, D. Vallera, 2010 .

Keratinocyte Growth Factor Administered Before Conditioning Ameliorates Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation in Mice

D. Lacey, B. Blazar, D. Vallera, 1998 .

Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice.

D. Lacey, B. Blazar, D. Vallera, 1998, Blood.

The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide.

P. Bitterman, D. Ingbar, B. Blazar, 1997, The Journal of clinical investigation.

Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-ricin toxin A chain immunotoxin.

B. Blazar, P. Taylor, D. Vallera, 1995, Blood.

Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow.

B. Blazar, P. Taylor, D. Vallera, 1994, Blood.

Effect of recombinant human macrophage colony-stimulating factor in irradiated murine recipients of T-cell-depleted allogeneic or non- depleted syngeneic bone marrow transplants

B. Blazar, D. Vallera, S. L. Aukerman, 1992 .

Effect of recombinant human macrophage colony-stimulating factor in irradiated murine recipients of T-cell-depleted allogeneic or non-depleted syngeneic bone marrow transplants.

B. Blazar, D. Vallera, S. L. Aukerman, 1992, Blood.

Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: Elimination of graft-versus-host disease without detrimental effects on engraftment

B. Blazar, D. Vallera, D. Thiele, 1990 .

Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: elimination of graft-versus-host disease without detrimental effects on engraftment.

B. Blazar, D. Vallera, D. Thiele, 1990, Blood.

Improved survival and leukocyte reconstitution without detrimental effects on engraftment in murine recipients of human recombinant granulocyte colony-stimulating factor after transplantation of T-cell-depleted histoincompatible bone marrow.

B. Blazar, D. Cosman, D. Vallera, 1989, Blood.

Augmentation of donor bone marrow engraftment in histoincompatible murine recipients by granulocyte/macrophage colony-stimulating factor.

B. Blazar, D. Vallera, S. Gillis, 1988, Blood.

donor graft preincubation with anti-LFA1 immunotoxin alloengraftment across the major histocompatibility barrier after Prevention of murine graft-versus-host disease and bone marrow

S. Carroll, B. Blazar, D. Vallera, 2011 .

Prevention of murine graft-versus-host disease and bone marrow alloengraftment across the major histocompatibility barrier after donor graft preincubation with anti-LFA1 immunotoxin.

S. Carroll, B. Blazar, D. Vallera, 1991, Blood.

T cell depletion for graft-versus-host-disease prophylaxis. A perspective on engraftment in mice and humans.

B. Blazar, D. Vallera, 1989, Transplantation.

The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins.

D. Vallera, D. Buchsbaum, J. Manske, 1989, Journal of immunology.

Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.

D. Arthur, D. Neville, R. Youle, 1987, Transplantation.

Monoclonal antibody toxin conjugates for experimental graft-versus-host disease prophylaxis. Reagents selectively reactive with T cells and not murine stem cells.

D. Neville, R. Youle, J. Kersey, 1983, Transplantation.

In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.

S. Carroll, B. Blazar, D. Vallera, 1991, Journal of immunology.

Assessment of multi-organ system engraftment by genotypic typing using restriction fragment-length polymorphisms and by phenotypic typing using a microcytotoxicity assay.

B. Blazar, D. Vallera, C. Soderling, 1986, Journal of immunology.

J. Kersey, D. Vallera, N. Ramsay, 1987 .

Ex Vivo and In Vivo Cytokine Studies in Irradiated Animals

B. Blazar, D. Vallera, 1993 .

B lymphocyte regulation of human hematopoiesis.

F. Uckun, D. Vallera, S. Wee, 1985, Journal of immunology.

In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts.

B. Bostrom, B. Blazar, J. Kersey, 1989, Blood.

Depressed leukocyte reconstitution and engraftment in murine recipients of T cell-depleted histoincompatible marrow pretreated with interleukin 3.

B. Blazar, D. Vallera, 1988, Transplantation.

Anti-T cell monoclonal antibodies conjugated to ricin as potential reagents for human GVHD prophylaxis: effect on the generation of cytotoxic T cells in both peripheral blood and bone marrow.

D. Neville, R. Youle, T. Lebien, 1984, Journal of immunology.

leukemic marrow progenitor cells immunotoxins and 4-hydroperoxycyclophosphamide against fresh acute lymphoblastic leukemia: efficacy of ex vivo treatment with Marrow purging in autologous bone marrow transplantation for T-lineage

J. Kersey, D. Vallera, N. Ramsay, 2013 .

Anti-CD2 (T, p50) intact ricin immunotoxins for GVHD-prophylaxis in allogeneic bone marrow transplantation.

D. Vallera, D. E. Myers, F. Uckun, 1986, Leukemia research.

Allogeneic and Autologous Marrow Transplantation: Ex vivo Purging with Monoclonal Antibody or Immunotoxins to Remove Leukemic Cells or to Prevent Graft Versus Host Disease

T. Lebien, J. Kersey, D. Vallera, 1986 .

Effect of IL-7 or IL-4 on reconstitution of donor lymphoid cells in congenic murine bone marrow transplantation.

B. Blazar, P. Taylor, D. Vallera, 1995, Bone Marrow Transplantation.

Ex vivo T cell depletion with immunotoxins in allogeneic bone marrow transplantation: The pilot clinical study for prevention of graft-versus-host disease

R. Youle, D. Vallera, A. Filipovich, 1985 .

Interleukin-1 or tumor necrosis factor-alpha antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice.

B. Blazar, P. Taylor, D. Vallera, 1995, Transplantation.

Murine gamma/delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens.

J. Bluestone, B. Blazar, P. Taylor, 1996, Blood.

Lipopolysaccharide-induced immunomodulation of the generation of cell-mediated cytotoxicity. I. Suppression of the development of cytotoxic lymphocytes.

D. Vallera, U. Pflugfelder, J. Schmidtke, 1980, Journal of immunology.

Lipopolysaccharide-induced immunomodulation of the generation cell-mediated cytotoxicity. II. Evidence for the involvement of a regulatory B lymphocyte.

D. Vallera, J. Schmidtke, C. E. Gamble, 1980, Journal of immunology.

Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

A. Skubitz, D. Vallera, Elizabeth P Taras, 2013, Gynecologic oncology.

Bone marrow transplantation across major histocompatability barriers in mice. III. Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants.

J. Kersey, D. Vallera, C. Soderling, 1982, Journal of immunology.

Bone marrow transplantation across major histocompatibility barriers in mice. II. T cell requirement for engraftment in total lymphoid irradiation-conditioned recipients.

J. Kersey, D. Vallera, G. J. Carlson, 1982, Transplantation.

MONOCLONAL ANTIBODY‐TOXIN CONJUGATES REACTIVE AGAINST HUMAN T LYMPHOCYTES: A COMPARISON OF ANTIBODY LINKED TO INTACT RICIN TOXIN WITH ANTIBODY LINKED TO RICIN A CHAIN

D. Vallera, R. Quinones, CHRISTINE C. B. SODERLING, 1984, Transplantation.

Use of Monoclonal Antibody-Intact Ricin Conjugates in Experimental Allogeneic Bone Marrow Transplantation

D. Neville, R. Youle, J. Kersey, 1984 .

Monoclonal Antibodies for Purging Bone Marrow of Acute Lymphoblastic Leukemia or Graft Versus Host Producing Cells:Antibody Plus Complement or Immunotoxins

D. Neville, R. Youle, T. Lebien, 1984 .

Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.

J. Bluestone, D. Snover, B. Blazar, 1993, Journal of immunology.

T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease.

B. Blazar, J. Kersey, D. Vallera, 1990, Transplantation.

Monoclonal Antibody Recognizing a Unique Rh‐Related Specificity

M. Telen, M. Poss, D. Vallera, 1993, Vox sanguinis.

Cell-type-specific cytotoxicity of anti-CD4 and anti-CD8 ricin immunotoxins against human alloreactive T-cell clones.

J. Ledbetter, F. Uckun, D. Vallera, 1989, Blood.

Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.

W. Hall, D. Vallera, Chunbin Li, 2002, Journal of the National Cancer Institute.

Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors

J. Modiano, E. Dickerson, D. Vallera, 2013, International journal of cancer.

Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies

V. Bachanova, D. Vallera, D. Todhunter, 2018, Toxins.

The role of T cell subsets in regulating the in vivo efficacy of CTLA4-Ig in preventing graft-versus-host disease in recipients of fully MHC or multiple minor histocompatibility-disparate donor inocula.

G. Gray, B. Blazar, P. Taylor, 1994, Transplantation.

Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.

Christopher R. So, V. Cody, C. Wagner, 2010, Journal of the American Chemical Society.

CD133, Selectively Targeting the Root of Cancer

D. Vallera, J. Schmohl, 2016, Toxins.

FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.

B. Blazar, P. Taylor, D. Vallera, 1994, Journal of immunology.

ASSESSMENT OF IMMUNOCOMPETENCE BY LIMITING DILUTION ANALYSIS IN LONG‐TERM T CELL DEPLETION CHIMERAS TRANSPLANTED ACROSS THE MHC BARRIER

C. Orosz, D. Vallera, C. Soderling, 1985, Transplantation.

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Jeffrey S. Miller, D. Weisdorf, D. Vallera, 2020 .

Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens.

W. Woods, F. Uckun, B. Bostrom, 1990, Bone marrow transplantation.

Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: clinical impact of immunophenotype and in vitro purging.

T. Lebien, D. Weisdorf, D. Vallera, 1991, Bone marrow transplantation.

AML ImmunoPET: 64Cu-DOTA-anti-CD33 PET-CT imaging of AML in Xenograft mouse model

J. Wong, J. Shively, I. Nair, 2019, bioRxiv.

Immunotoxin targeting CD133+ breast carcinoma cells

J. Panyam, D. Vallera, J. Ohlfest, 2012, Drug Delivery and Translational Research.

Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer

W. Hall, J. Massagué, D. Vallera, 2012, Journal of Neuro-Oncology.

Radiotherapy of CD45-expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibody.

M. Brechbiel, D. Vallera, L. Burns, 2007, Cancer biotherapy & radiopharmaceuticals.

Cimetidine induced augmentation of murine cell mediated cytotoxicity after in vitro and in vivo treatment. Abstr.

D. Vallera, R. Gifford, 1980 .

Prosthetic Antigen Receptors.

C. Wagner, D. Vallera, Jingjing Shen, 2015, Journal of the American Chemical Society.

Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.

D. Vallera, J. Ohlfest, Alexander K. Tsai, 2011, Journal of neurosurgery.

Reversible re-programing of cell-cell interactions.

C. Wagner, D. Vallera, Nigam Kumar, 2014, Angewandte Chemie.

Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model

B. Stish, A. Saluja, S. Vickers, 2008, Gut.

A Bispecific Recombinant Cytotoxin (DTEGF13) Targeting Human Interleukin-13 and Epidermal Growth Factor Receptors in a Mouse Xenograft Model of Prostate Cancer

B. Stish, D. Vallera, Hua Chen, 2007, Clinical Cancer Research.

The effect of T subset depletion on the incidence of lethal graft-versus-host disease in a murine major-histocompatibility-complex-mismatched transplantation system.

B. Blazar, D. Vallera, D. Pietryga, 1987, Transplantation.

A novel brain metastasis xenograft model for convection‑enhanced delivery of targeted toxins via a micro‑osmotic pump system enabled for real‑time bioluminescence imaging.

W. Hall, Q. Cheng, D. Vallera, 2015, Molecular medicine reports.

Allogeneic and autologous bone marrow transplantation for acute lymphoblastic leukemia.

W. Woods, T. Lebien, F. Uckun, 1990, Haematology and blood transfusion.

Identification and characterization of a novel scFv recognizing human and mouse CD133

J. Panyam, D. Vallera, J. Ohlfest, 2013, Drug Delivery and Translational Research.

Immunotoxin targeting CD133+ breast carcinoma cells

J. Panyam, D. Vallera, J. Ohlfest, 2013, Drug Delivery and Translational Research.

Anti-NKG2C/IL-15/anti-CD33 Killer Engager Directs Primary and iPSC-derived NKG2C+ NK cells to Specifically Target Myeloid Leukemia.

Jeffrey S. Miller, K. Malmberg, D. Vallera, 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature

D. Vallera, J. Ohlfest, Alexander K. Tsai, 2011, Journal of Neuro-Oncology.

Treatment of mice with anti-CD3 mAb induces endothelial vascular cell adhesion molecule-1 expression.

C. Orosz, S. Bergese, R. Ohye, 1994, Transplantation.

A New Drug Delivery Method of Bispecific Ligand-Directed Toxins, Which Reduces Toxicity and Promotes Efficacy in a Model of Orthotopic Pancreatic Cancer

B. Stish, A. Saluja, S. Vickers, 2010, Pancreas.

Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.

D. Vallera, Seunguk Oh, Nate N. Waldron, 2012, Oral oncology.

In vitro efficacy of recombinant diphtheria toxin-murine interleukin-4 immunoconjugate on mouse glioblastoma and neuroblastoma cell lines and the additive effect of radiation.

K U Kim, W. Hall, W. Low, 2000, Neurosurgical focus.

A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma

B. Stish, D. Sachdev, D. Vallera, 2009, Clinical Cancer Research.

IL-15/B7-H3 TriKEs-Based Immunotherapy for Pancreatic Ductal Adenocarcinoma

C. Ferrone, S. Ferrone, D. Vallera, 2019, Journal of the American College of Surgeons.

Short-course total-lymphoid irradiation combined with total-body irradiation to facilitate engraftment of T cell-depleted marrow across a major histocompatibility barrier in mice.

B. Blazar, D. Vallera, L. Robison, 1988, Transplantation.

Kupffer Cell Engraftment Across the Major Histocompatibility Barrier in Mice: Bone Marrow Origin, Class II Antigen Expression, and Antigen‐Presenting Capacity

B. Blazar, D. Vallera, K. Paradis, 1990, Journal of Pediatric Gastroenterology and Nutrition - JPGN.

Allogeneic and autologous bone marrow transplantation for high risk acute lymphoblastic leukemia.

F. Uckun, B. Jansen, D. Weisdorf, 1992, Leukemia.

Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA

D. Vallera, M. Felices, B. Kodal, 2023, Immuno.

Bispecific Targeted Toxin DTATEGF Against Metastatic NSCLC Brain Tumors

W. Hall, D. Vallera, Jun Huang, 2014 .

CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics

J. Tolar, Jeffrey S. Miller, S. Spellman, 2016 .

Immunotherapy of a murine sarcoma using specific antitumor immune RNA

D. Vallera, D. Webster, J. Cornacoff, 1979, Journal of surgical oncology.

Trispecific Killer Engagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion

J. Tolar, Bin Zhang, Jeffrey S. Miller, 2015 .

Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia

Jeffrey S. Miller, J. Gotlib, D. Weisdorf, 2017, American journal of hematology.

Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.

M. Jenkins, J. White, R. Korngold, 1997, Journal of immunology.

Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin

D. Vallera, D. Todhunter, A. Borgatti, 2018, Clinical pharmacology : advances and applications.

444 GTB-3550 tri-specific killer engager TriKE™ drives NK cells expansion and cytotoxicity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients

D. Vallera, E. Warlick, M. Felices, 2021, Journal for ImmunoTherapy of Cancer.

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Jeffrey S. Miller, B. Blazar, D. Vallera, 2019, Blood.

Design, Characterization, and Evaluation of scFvCD133/rGelonin: A CD133-Targeting Recombinant Immunotoxin for Use in Combination with Photochemical Internalization

K. Berg, M. Rosenblum, A. Weyergang, 2019, Journal of Clinical Medicine.

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

D. Munn, J. Tolar, B. Levine, 2009, Blood.

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition

Bin Zhang, Jeffrey S. Miller, J. Ross, 2013, Clinical Cancer Research.

Self-assembly of antibodies by chemical induction.

C. Wagner, D. Vallera, Qing Li, 2008, Angewandte Chemie.

Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases

A. Frankel, D. Vallera, Hua Chen, 2010, Molecular Cancer Therapeutics.

Targeting Tumor-Initiating Cancer Cells with dCD133KDEL Shows Impressive Tumor Reductions in a Xenotransplant Model of Human Head and Neck Cancer

D. Kaufman, D. Vallera, J. Ohlfest, 2011, Molecular Cancer Therapeutics.

Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.

D. Vallera, J. Ohlfest, Alexander K. Tsai, 2011, Journal of Neurosurgery.

Hemangiosarcoma and its cancer stem cell sub-population are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors

E. Dickerson, D. Vallera, B. H. Gorden, 2013, BMC Proceedings.

D. Neville, R. Youle, J. Kersey, 1982, The Journal of experimental medicine.

Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models

Jeffrey S. Miller, D. Weisdorf, M. Geller, 2017 .